morpholineoethylamino-3-benzocyclohepta(5,6-c)pyridazine: structure given in first source; selective M1 muscarinic agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 195164 |
| SCHEMBL ID | 10389077 |
| MeSH ID | M0169823 |
| Synonym |
|---|
| 115767-94-7 |
| PRESTWICK_765 , |
| sr-95639a |
| HMS1569A14 |
| morpholineoethylamino-3-benzocyclohepta(5,6-c)pyridazine |
| 5h-benzo(6,7)cyclohepta(1,2-c)pyridazin-3-amine, 6,7-dihydro-n-(2-(4-morpholinyl)ethyl)-, dihydrochloride |
| CCG-220406 |
| SCHEMBL10389077 |
| DTXSID40151186 |
| sr-01000841214 |
| SR-01000841214-2 |
| n-(2-morpholinoethyl)-6,7-dihydro-5h-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-amine dihydrochloride |
| n-(2-morpholin-4-ylethyl)-3,4-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-5-amine;dihydrochloride |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||